4-HO-DSBT

4-HO-DSBT structure

4-HO-DSBT: A Deep Dive into Its Serotonergic Mechanism

4-HO-DSBT or 4-hydroxy-N,N-di-sec-butyltryptamine, is a compound that belongs to the expansive tryptamine class. These compounds are renowned for their interactions with serotonin receptors, often resulting in varying degrees of psychoactive effects.

Historical Overview

The origins of 4-HO-DSBT can be traced back to the pioneering work of Dr. Alexander Shulgin. While Shulgin was the first to synthesize the compound, it is noteworthy that he did not carry out any tests on it^[1]. His documentation in the renowned book "TiHKAL" (Tryptamines I Have Known And Loved) provides an archival insight into its synthesis.

Pharmacological Profile

Serotonin Receptor Agonism: 4-HO-DSBT acts primarily as an agonist at the serotonin receptors. Agonism at these receptors is indicative of the compound's potential to produce psychoactive effects, given the central role of serotonin in mood regulation and perception.

Comparison with Isomers: Subsequent in vitro studies have differentiated 4-HO-DSBT from its n-butyl and isobutyl isomers. The s-butyl derivative (i.e., 4-HO-DSBT) was found to have a higher potency than its counterparts^[2].

5-HT2A Receptor Affinity: The 5-HT2A receptor affinity of 4-HO-DSBT is akin to that of MiPT, positioning it as a potent compound in the serotonergic agonism spectrum^[3].

Selectivity over 5-HT1A and 5-HT2B: One of the distinguishing features of 4-HO-DSBT is its heightened selectivity for the 5-HT2A receptor over the 5-HT1A and 5-HT2B subtypes. Such selectivity offers potential advantages in minimizing off-target effects and highlights its unique pharmacodynamic profile^[4].

Implications for Research and Medicine

Given its distinctive serotonergic profile, 4-HO-DSBT holds promise as a molecular tool for studying the serotonin system. Understanding its mechanism can provide insights into mood disorders, cognition, and perception. Further research into its safety profile, pharmacokinetics, and potential therapeutic applications is essential.

Conclusion

4-HO-DSBT, an intricate compound synthesized by Dr. Alexander Shulgin, offers a fascinating glimpse into the world of tryptamines and their interactions with the serotonin system. As researchers delve deeper into its pharmacological properties, the compound might pave the way for novel therapeutic avenues and a deeper understanding of serotonergic signaling.

References

↑ Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press.
↑ Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.
↑ Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.
↑ Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Transform your life with W8MD's budget GLP-1 injections from $125.

W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:

- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC

Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[tihkal-1] Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press.

[research1-2] Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.

[research2-3] Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.

[selectivity3-4] Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.

[1]

[2]

[3]

[4]